Search

Due to favorable physical properties of 141Ce radionuclide [E βmax = 434.6 keV (70.5%) and 580.0 keV (29.5%), E γ = 145.4 keV, and physical half-life = 32.5 day], a complex including this radionuclide could be a good candidate for palliative therapy of metastatic bone patients and an alternative to 89SrCl2 as a FDA-approved radiopharmaceutical. Because the bone marrow absorbed dose is a limiting factor in the palliative therapy of bone metastases, this study conducted to calculate the bone marrow absorbed dose of 141Ce-EDTMP complex and compare it with the 89SrCl2 using Monte Carlo simulation. In this study, the GATE Monte Carlo toolkit and two human bone models including vertebra and femur bones were used for simulations. The vertebra and femur bone marrow absorbed dose from 141Ce-EDTMP were 29.1 and 4.3 mGy/MBq, respectively. Moreover, the vertebra and femur bone marrow absorbed dose from 89SrCl 2 were 109.2 and 16.3 mGy/MBq, respectively. Bone-to-bone marrow absorbed dose ratio in the vertebra for 141Ce-EDTMP and 89SrCl 2 was 34.2 and 11.6, respectively, whereas, this ratio in the femur was 23.8 and 7.5, respectively. Owing to the high bone-to-bone marrow absorbed dose ratio and lower bone marrow absorbed dose than 89SrCl 2 , 141Ce-EDTMP could be a promising new complex for palliative therapy of patients with bone metastasis. • Vertebra and femur bone models were considered for bone marrow dosimetry of 141Ce-EDTMP. • Bone marrow dosimetry was performed for 141Ce-EDTMP and 89Sr–Cl 2 using the GATE and MIRD method. • The obtained results for 89Sr–Cl 2 have been compared with the ICRP 140. [ABSTRACT FROM AUTHOR]